ACE2 and metabolic syndrome: Significantly higher median ACE2 levels at presentation were found in patients with dyslipidemia compared to those without (9.15 vs. 4.13 ng/mL; p = 0.002), whereas median TMPRSS2 levels did not show significant differences (8.34 vs. 4.75; p = 0.099) (Supplementary Table S1).